New pill combo shows promise for Hard-to-Treat lung cancer mutation
NCT ID NCT04526782
First seen Jun 25, 2026 · Last updated Aug 12, 2026 · Updated 3 times
Summary
This phase 2 study tests two targeted drugs, encorafenib and binimetinib, in 119 people with advanced non-small cell lung cancer that has a specific BRAF V600E mutation. The goal is to see if the combination can shrink tumors and keep them from growing. Participants take the pills daily and are monitored for response and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- encorafenib and binimetinib (targeted therapy pills)
- What this could lead to
- If successful, this combination could offer a new targeted treatment option for people with a specific genetic mutation in advanced lung cancer.
- What could go wrong
- This is a mid-stage trial with only 119 participants, so results may not apply to everyone. Targeted therapies can stop working over time and may cause side effects like skin or eye problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAF V600E are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AP-HM Hôpital Nord
Marseille, France
-
AP-HP Hôpital Cochin
Paris, 75014, France
-
AP-HP Hôpital Tenon
Paris, 75970, France
-
Angers - CHU
Angers, France
-
Annemasse - CH
Ambilly, 74100, France
-
Avignon - Institut Sainte-Catherine
Avignon, 84918, France
-
Bordeaux - Institut Bergonié
Bordeaux, France
-
Boulogne - Ambroise Paré
Boulogne-Billancourt, France
-
Brest - CHU
Brest, France
-
CH
Colmar, France
-
CH Le Mans
Le Mans, France
-
CHRU Grenoble
Grenoble, France
-
CHRU de Lille
Lille, France
-
CHU Charles Nicolle
Rouen, France
-
CHU Dupuytren
Limoges, 87042, France
-
CHU Rennes - Hôpital Pontchaillou
Rennes, 35033, France
-
CHU Toulouse - Pneumologie
Toulouse, France
-
Caen - CHU Côte de Nacre
Caen, 14000, France
-
Centre Antoine LACASSAGNE
Nice, France
-
Centre Georges François Leclerc
Dijon, France
-
Centre Hospitalier Général - Pau
Pau, 64000, France
-
Centre Hospitalier Intercommunal de Créteil
Créteil, 94000, France
-
Centre Léon Bérard
Lyon, 69000, France
-
Gustave Roussy
Villejuif, 94805, France
-
Hôpital BICHAT
Paris, France
-
Institut Paoli Calmettes
Marseille, 13273, France
-
La Roche Sur Yon - CH
La Roche-sur-Yon, 85925, France
-
Lyon - URCOT
Pierre-Bénite, France
-
Montpellier - CHRU
Montpellier, 34295, France
-
Mulhouse - GHRMSA
Mulhouse, France
-
Nancy - Institut de Cancérologie de Lorraine
Nancy, France
-
Nouvel Hôpital Civil - Hôpitaux Universitaires de Strasbourg
Strasbourg, 67091, France
-
Paris - Institut Curie
Paris, France
-
Saint Quentin - CH
Saint-Quentin, 02100, France
-
Tours - CHU
Tours, 37000, France
-
Villefranche-Sur-Saône - Hôpital Nord-Ouest
Villefranche-sur-Saône, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?